-
BioMarin to Cut 225 Jobs Amid Challenges in Gene Therapy Commercialization
•
US-based BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is navigating a challenging period marked by difficulties in commercializing its gene therapies. In a recent SEC filing, the company announced plans to reduce its workforce by 225 employees as part of its “organizational redesign efforts.” The restructuring is tied to BioMarin’s revised commercial…
-
BioMarin Pharmaceutical to Discontinue Vimizim Import License in China
•
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) has announced its decision not to renew the Import Drug License (IDL) for Vimizim (elosulfase alfa) in China when it expires in May 2024. The company is currently exploring feasible ways to ensure a continuous supply to patients currently undergoing treatment. Challenges in China’s Market…
